Experienced in Dihydropyrimidine Dehydrogenase Deficiency

Filippo Pietrantonio

Milan, IT 
Experienced in Dihydropyrimidine Dehydrogenase Deficiency
Milan, IT 
OverviewLocationsClinical Research

Overview

Filippo Pietrantonio practices in Milan, Italy. Mr. Pietrantonio is rated as an Experienced expert by MediFind in the treatment of Dihydropyrimidine Dehydrogenase Deficiency. His top areas of expertise are Colorectal Cancer, Stomach Cancer, Pseudomyxoma Peritonei, Hepato-Pancreato-Biliary Surgery, and Tissue Biopsy.

His clinical research consists of co-authoring 357 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Dihydropyrimidine Dehydrogenase Deficiency.

Gender
Male

Locations

Milan, Italy
Other Locations
Rome, Italy
Via Giacomo Venezian 1, Via, 20133, Italy
Padova, Italy
70124, Italy
Bari, Italy
Verona, 37100, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase I/II Study Exploring the Safety and Activity of Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients
A Phase I/II Study Exploring the Safety and Activity of Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: June 06, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Enrollment Status: Unknown
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: CAPOX, Capecitabine, FOLFIRI
Study Phase: Phase 2
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study
Enrollment Status: Completed
Publish Date: April 04, 2022
Intervention Type: Drug
Study Phase: Phase 2
Open-label, Randomized, Multicenter, Phase II Trial to Compare Efficacy of CAPTEM Versus FOLFIRI as Second Line in Patients Progressed on or After First-line Oxaliplatin Chemo for Advanced, MGMT Methylated, RAS Mutated Colorectal Cancer
Open-label, Randomized, Multicenter, Phase II Trial to Compare Efficacy of CAPTEM Versus FOLFIRI as Second Line in Patients Progressed on or After First-line Oxaliplatin Chemo for Advanced, MGMT Methylated, RAS Mutated Colorectal Cancer
Enrollment Status: Completed
Publish Date: September 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES
PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES
Enrollment Status: Completed
Publish Date: August 07, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

357 Total Publications

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pietrantonio's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile